Nasal Peptide Sprays: Administration Technique for Selank, Semax, and PT-141

Intranasal administration occupies a narrow but well-characterized niche in peptide research. Most peptides are too large, too hydrophilic, or too enzymatically fragile to cross the nasal mucosa in meaningful quantities, but a small subset — short regulatory peptides and certain melanocortin analogues — show reproducible intranasal bioavailability in published pharmacokinetic work. For researchers handling Selank, Semax, PT-141, or Oxytocin, administration technique is not a trivial variable; it materially affects how much compound reaches the target tissue and how consistent dose-to-dose delivery is.

Which Peptides Have Meaningful Intranasal Bioavailability

The rationale for the intranasal route is twofold. First, the nasal mucosa is thin, highly vascularized, and bypasses hepatic first-pass metabolism. Second, for neuroactive peptides, the olfactory and trigeminal pathways offer a potential route of direct nose-to-brain transport, avoiding the blood-brain barrier entirely. Both mechanisms have been characterized in rodent and human studies, though the fraction of an applied dose that actually reaches brain tissue remains the subject of active debate.

Selank and Semax are the two most frequently studied intranasal peptides in the Russian pharmacological literature, where both compounds were originally developed. Published pharmacokinetic work on Semax reports measurable CNS penetration within minutes of intranasal administration in rodent models, with effects on BDNF and NGF expression described in multiple studies from the Myasoedov group and collaborators. Selank, a synthetic analogue of tuftsin, has been studied intranasally in both rodent anxiolytic models and small human trials, with reported plasma half-life in the range of several minutes and behavioural effects persisting considerably longer — a dissociation typically attributed to downstream receptor signalling rather than prolonged peptide exposure.

PT-141 (bremelanotide) was originally developed as an intranasal formulation before its clinical program shifted to subcutaneous injection. The intranasal version reached late-stage human trials for sexual dysfunction indications; the shift away from intranasal delivery was driven primarily by variability in absorption and blood pressure response, not by a complete failure of the route. Researchers working with PT-141 intranasally should expect greater dose-to-dose variability than with subcutaneous injection.

Oxytocin has been studied intranasally in a large body of human social-cognition literature, though the extent to which intranasal oxytocin actually reaches central receptors has been questioned in several recent reviews. Effect sizes reported in behavioural studies are generally modest, and dose-response relationships are non-monotonic in multiple published trials.

Peptides that do not show meaningful intranasal bioavailability include most of the growth-hormone-releasing peptides (CJC-1295, Ipamorelin, Tesamorelin), the body-composition compounds (Retatrutide, Tirzepatide), and the repair peptides (BPC-157, TB-500). These are too large, too rapidly degraded by nasal peptidases, or both, and are not candidates for the intranasal route regardless of formulation.

How Metered Nasal Sprays Work

A research-grade nasal spray is a pressure-driven metering pump mounted on a small bottle of aqueous peptide solution. Each actuation draws a fixed volume — typically 50, 100, or 140 microlitres — from the reservoir through a dip tube, pressurizes it through a one-way valve, and atomizes it through a narrow orifice into a cone-shaped plume. The spray pattern, droplet size distribution, and deposition zone within the nasal cavity are determined by the pump geometry, not by how hard the user presses.

Peptide concentration is adjusted so that one or two actuations deliver the intended dose. A common configuration for Selank and Semax is a 1% solution (10 mg/mL) in a 100-microlitre metered pump, delivering 1 mg per actuation. PT-141 intranasal formulations studied in the clinical literature typically targeted lower microgram-range doses per actuation. Researchers should confirm the concentration and metered volume of any given preparation rather than assuming a standard.

Priming matters. A fresh or recently unused pump contains air in the dip tube and pump chamber; the first several actuations will deliver partial or no dose until the system is primed. Published pump specifications typically require three to seven priming actuations before first use, and one to two re-priming actuations if the pump has been idle for more than a day. Priming sprays should be discharged into a tissue, not into the nasal cavity, since the discharged volume is not accurate.

Head Positioning and the Bilateral Technique

The goal of administration technique is to deposit the spray plume on the respiratory mucosa of the middle and upper nasal cavity, where vascular uptake is highest and — for neuroactive peptides — where the olfactory region is accessible. The goal is explicitly not to deliver the plume to the back of the throat, where it will be swallowed and subjected to gastric degradation.

The technique that best achieves this, described in multiple intranasal pharmacokinetic papers, is as follows:

• Head held upright or tilted slightly forward, not tilted back.
• One nostril gently closed with a fingertip against the septum.
• Nozzle inserted a short distance into the open nostril, angled outward toward the ipsilateral ear rather than straight up toward the eye.
• A single firm actuation coordinated with a light, slow inhalation through that nostril.
• Brief pause, then the same procedure repeated on the opposite side.

Tilting the head back, which is intuitive but incorrect, tends to route the plume directly into the nasopharynx where it drains into the throat. Angling the nozzle toward the lateral wall of the nasal cavity rather than the septum reduces irritation and improves deposition on the turbinate surfaces where absorption occurs.

Bilateral administration — one actuation per nostril rather than two in the same nostril — is standard in the published Selank and Semax protocols and in the PT-141 clinical trial materials. Splitting the dose across both nostrils roughly doubles the available mucosal surface area for a given total volume and reduces the fraction of compound lost to runoff.

Sniffing Pressure, Breath Coordination, and Wait Times

Coordinating the spray with inhalation is a subtle but consequential variable. A hard sniff creates high airflow velocity through the nasal valve, which tends to carry the plume past the absorptive turbinate surfaces and deposit it in the nasopharynx — the same failure mode as head-tilt-back. A light, slow inhalation creates gentler laminar flow that allows the plume to settle on the mucosa.

In practice, the inhalation should be just strong enough to feel the spray enter the cavity, not strong enough to feel it in the throat. If the researcher tastes the compound at the back of the throat shortly after administration, the technique has failed on that actuation and a portion of the dose has been swallowed rather than absorbed nasally.

After each actuation, a brief quiet-breathing pause of roughly thirty seconds before the next actuation allows the mucosa to absorb the deposited plume rather than have it displaced by the subsequent spray. A longer wait of ten to fifteen minutes before eating, drinking, or blowing the nose is commonly specified in clinical study protocols to allow absorption to complete. Forceful nose-blowing within the first few minutes after administration will expel a meaningful fraction of the undissolved dose.

Saline rinses, decongestant sprays, and antihistamine sprays all alter the nasal mucosa and should not be co-administered with peptide sprays within a short window. Published intranasal pharmacokinetic work typically excludes subjects with active rhinitis, since mucosal inflammation and increased mucus production substantially change absorption kinetics.

Storage, Stability, and Handling of Reconstituted Sprays

Peptide nasal sprays are aqueous solutions and are considerably less stable than lyophilized powder. Published stability data for Selank and Semax solutions, and manufacturer specifications for bremelanotide intranasal formulations, converge on a refrigerated shelf life of roughly thirty days for most preservative-containing formulations, with shorter windows for preservative-free preparations.

Refrigeration at standard 2–8°C is the default. Freezing reconstituted solutions is generally avoided because freeze-thaw cycles can cause peptide aggregation and loss of activity; a spray that has been accidentally frozen should be considered compromised. Exposure to direct light and to elevated temperatures accelerates degradation, particularly for peptides containing tryptophan or methionine residues.

Preservatives — typically benzalkonium chloride or phenylethyl alcohol in commercial formulations — extend stability but are themselves irritating to the nasal mucosa with chronic exposure and have been reported to alter ciliary function in prolonged use. Preservative-free preparations avoid this issue at the cost of a shorter in-use shelf life, typically one to two weeks refrigerated after first actuation.

Between uses, the pump should be stored upright with the cap replaced. The nozzle tip can be wiped with a clean dry tissue; it should not be rinsed under tap water, which can contaminate the pump chamber on the next actuation. Cross-use of the same pump between researchers is not appropriate for infection-control reasons regardless of the peptide involved.

Dose Verification and Practical Limits of the Route

Intranasal dosing is inherently less precise than subcutaneous injection. The metered pump delivers a consistent volume, but the fraction of that volume that actually reaches systemic or central circulation varies with mucosal condition, technique, and formulation. Reported intranasal bioavailability for small neuropeptides ranges broadly across studies, and published values should be read as order-of-magnitude estimates rather than precise numbers.

For compounds where dose-response is steep or where cardiovascular effects are dose-dependent — PT-141 is the clearest example, given its pressor response — the variability of the intranasal route is a meaningful limitation. Subcutaneous administration, though less convenient, gives substantially more reproducible plasma exposure and is preferred in most current PT-141 research protocols. For Selank and Semax, where therapeutic windows appear wider in the published literature and effects are primarily central, the intranasal route remains the primary administration mode in most published protocols.

Researchers tracking their own protocol outcomes should log actuation count, nostril sequence, time-of-day, and subjective onset timing rather than relying on nominal dose alone. Technique drift — gradually tilting the head back, sniffing harder over time, reducing the inter-actuation pause — is common and is one of the more frequent explanations for apparent loss of effect over a cycle.

Open Questions

The extent of true nose-to-brain transport for peptides in humans remains contested. Rodent olfactory anatomy differs substantially from human olfactory anatomy, and the fraction of an intranasal dose that reaches human CNS tissue via non-systemic routes has not been directly quantified in living subjects. Behavioural effects reported for intranasal Oxytocin, Selank, and Semax are consistent with central activity, but the route by which the peptide arrives there — direct olfactory, systemic-then-BBB, or indirect via peripheral receptor signalling — is not fully resolved. Future work using labeled peptides and more sensitive CNS sampling methods is likely to narrow these questions rather than answer them definitively in the near term.